Live symbol workspace

GILD market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Current $134.38

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$127.66

Resistance

$141.10

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Context

Current price

$134.38

RSI context

50

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

30%

▼ 7.5 pts vs previous week

Avg confidence across 7 calls in the last 7 days

What sources say

Bearish 1 article

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?

Insider Trading

Refreshing insider trades from FinViz…

Technical Observations

Refreshing technical observations from FinViz...

GILD News Intelligence (5 articles)

AI-curated news influencing GILD price, sentiment, and trend

Explore All GILD News with AI Analysis

Economy

1 week ago

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?

Over the last six months, Gilead Sciences’s shares have sunk to $137.77, producing a disappointing 11.3% loss - a stark …

Impact on GILD: GILD's decline may lead to sector rotation, potentially benefiting competitors or other …

Gilead Sciences' (GILD) shares have declined 11.3% over the last six months, underperforming the S&P … Medium (60%)

View full analysis →

Yahoo Finance 60% confidence

Economy

1 month, 1 week ago

Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.

Gilead's expansion beyond HIV therapies will surprise many investors.

Impact on GILD: The upcoming drug launches could lead to a surge in Gilead Sciences' …

Gilead Sciences is poised to launch 4 new drugs this year, potentially surprising investors who … High (70%)

View full analysis →

Yahoo Finance 70% confidence

Economy

1 month, 3 weeks ago

Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, …

Impact on GILD: Neutral market sentiment indicated

Analysis of stock market developments showing neutral sentiment. Medium (50%)

View full analysis →

Yahoo Finance 50% confidence

Economy

2 months ago

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings?

Since December 2025, Gilead Sciences has been in a holding pattern, posting a small return of 2.7% while floating around …

Impact on GILD: Potentially positive price action expected

Analysis of stock market developments showing bullish sentiment. Medium (60%)

View full analysis →

Yahoo Finance 60% confidence

Economy

3 months ago

US Ebola Aid Plummets 99% Since Last Outbreak

Former Executive Director of the USAID COVID-19 Task Force Jeremy Konyndyk joined Bloomberg This Weekend to discuss the Ebola outbreak …

Impact on GILD: The decrease in US Ebola aid may lead to increased volatility in …

The US aid for Ebola has decreased by 99% since the last outbreak, which may … Medium (60%)

View full analysis →

Bloomberg 60% confidence